CJC-1295 (No DAC) vs PEG-MGF
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically a modified GHRH(1-29). The name covers two different products. CJC-1295 with DAC (Drug Affinity Complex) binds blood albumin, which stretches its half-life to roughly 6 to 8 days and raises GH and IGF-I for days from a single injection; this is the version ConjuChem took to Phase II before abandoning it, and the version the human data are about. CJC-1295 without DAC (Modified GRF 1-29, the form this page is named for) lacks the albumin tether and is much shorter acting, though its human half-life has not been formally published. Neither is an approved drug, both are sold only as research chemicals, and GHRH analogs are banned in sport by WADA.
Also: Pegylated MGF, PEGylated Mechano Growth Factor
PEG-MGF is MGF (the synthetic E-domain peptide from the IGF-1Ec splice variant) with a polyethylene glycol chain attached to make it last longer in the body. That is the theory, anyway. We have to be blunt: there is essentially no published research on PEG-MGF itself. A 2026 clinical review of growth-axis peptides put it in its lowest evidence tier, with no peer-reviewed human studies and no published half-life. Everything said about it online is borrowed from MGF lab work, and MGF's own evidence is shaky.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- CJC-1295 (No DAC) has stronger research evidence (Limited Human Data) compared to PEG-MGF (Limited Research).
Detailed Comparison
| Attribute | CJC-1295 (No DAC) | PEG-MGF |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 acts at the GHRH receptor on pituitary somatotroph cells, the same receptor the body's own GHRH uses, prompting the pituitary to synthesize and release growth hormone. Native GHRH is broken down within minutes; CJC-1295 with DAC carries a reactive group that covalently bonds to circulating albumin after injection, shielding it from breakdown and stretching its half-life from minutes to days. The sustained GH elevation drives the liver to produce IGF-I, the downstream hormone behind many of GH's tissue effects. There are two versions: with DAC (long-acting, albumin-binding) and without DAC (Modified GRF 1-29), which lacks the albumin tether. Because it works through the pituitary, it relies on the gland's own GH-producing capacity. | Pegylation is a real, well-understood drug technique: attaching PEG makes a molecule bigger, slows how fast the kidneys clear it, and shields it from enzymes. It works for approved drugs, and a pegylated version of full IGF-1 (a different molecule) showed a half-life of 140 to 200 hours in a 2017 first-in-human study. The pitch for PEG-MGF is that the same trick lets the short-lived MGF peptide circulate long enough to act on muscle throughout the body. But PEG also changes how a molecule binds and where it goes, so effects reported for unmodified MGF cannot simply be assumed to carry over. The 2026 review made exactly that point. And since the underlying MGF mechanism was not reproduced in a 2014 pharma study, PEG-MGF is a modification of a hypothesis. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 200-400 mcg 2-3x per week (forum-reported) 2-3x weekly in forum protocols |
| Administration | Subcutaneous injection | Subcutaneous or intramuscular injection (forum-reported) |
| Typical Duration | 8-12 weeks | Forum protocols describe 8-16 week cycles with about 4 weeks off; no studied duration exists |
| Best Time to Take | Before bed | Not established (forums suggest post-workout) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The key human study is Teichman et al. (2006) in the Journal of Clinical Endocrinology and Metabolism, a randomized, double-blind, placebo-controlled ascending-dose trial in healthy adults using the DAC version. A single subcutaneous injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with cumulative effects on repeat dosing, and was reported as safe and relatively well tolerated short-term. A follow-up study in healthy men found GH still came in pulses rather than a flat line, with trough GH levels rising sharply. An earlier study showed once-daily CJC-1295 normalized growth in GHRH-knockout mice. These are hormone-level and pharmacokinetic studies, not outcome trials: there are no long-term human trials showing fat loss or muscle gain, and no published randomized trial of the popular CJC-1295 plus ipamorelin combination. The no-DAC form has essentially no published human data of its own. Development was halted after Phase II; a single trial death was attributed by the attending physician to pre-existing coronary artery disease rather than the drug, which is reported but not independently confirmed. FDA has also noted reported adverse events including increased heart rate and a systemic vasodilatory reaction. Bottom line: the GH and IGF-I-raising effect of the DAC version is well supported, while real-world efficacy and long-term safety are not. | Searching PubMed for PEG-MGF returns essentially one relevant hit: a 2026 narrative review in Frontiers in Endocrinology (Dominikowski and colleagues) on performance peptides that target the GH and IGF-1 axis. It rated PEG-MGF tier D: no peer-reviewed human studies, no reported route of administration in clinical research, half-life not reported, and safety concerns that are theoretical (based on MGF's link to cancer-cell growth in lab studies). The doses that circulate come from bodybuilding forums, which the review summarized only so doctors can recognize what patients are doing, not as guidance. Everything else people cite is MGF research: cell and animal studies suggesting muscle and heart repair effects, plus a careful 2014 study by Fornaro and colleagues that found no effect of MGF on muscle cells, and no effect of native or stabilized MGF on a separate signaling readout in heart cells. If you are looking for evidence that PEG-MGF builds muscle in humans, it does not exist yet. |
Frequently Asked Questions: CJC-1295 (No DAC) vs PEG-MGF
What is the difference between CJC-1295 (No DAC) and PEG-MGF?
CJC-1295 (No DAC) is a growth hormone peptide that cjc-1295 is a synthetic analog of growth hormone-releasing hormone (ghrh), specifically a modified ghrh(1-29). the name covers two different products. cjc-1295 with dac (drug affinity complex) binds blood albumin, which stretches its half-life to roughly 6 to 8 days and raises gh and igf-i for days from a single injection; this is the version conjuchem took to phase ii before abandoning it, and the version the human data are about. cjc-1295 without dac (modified grf 1-29, the form this page is named for) lacks the albumin tether and is much shorter acting, though its human half-life has not been formally published. neither is an approved drug, both are sold only as research chemicals, and ghrh analogs are banned in sport by wada. PEG-MGF is a growth hormone peptide that peg-mgf is mgf (the synthetic e-domain peptide from the igf-1ec splice variant) with a polyethylene glycol chain attached to make it last longer in the body. that is the theory, anyway. we have to be blunt: there is essentially no published research on peg-mgf itself. a 2026 clinical review of growth-axis peptides put it in its lowest evidence tier, with no peer-reviewed human studies and no published half-life. everything said about it online is borrowed from mgf lab work, and mgf's own evidence is shaky. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 (No DAC) or PEG-MGF?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 (No DAC) is typically used for growth hormone purposes, while PEG-MGF is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 (No DAC) and PEG-MGF be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 (No DAC) and PEG-MGF together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.